Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Your search for S1PR4 returned no results
Showing 1 result for s1pr

  1. Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)

    Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

    Technology appraisal guidance
    Published
    9 June 2021
    View recommendations

    Sections for TA706